HC Wainwright Predicts ALX Oncology FY2029 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – HC Wainwright issued their FY2029 earnings per share estimates for ALX Oncology in a note issued to investors on Friday, January 24th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.63 per share for the year. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

A number of other analysts also recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Finally, UBS Group dropped their target price on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $3.05.

ALX Oncology Stock Down 1.6 %

NASDAQ ALXO opened at $1.53 on Monday. The company has a market cap of $80.69 million, a price-to-earnings ratio of -0.51 and a beta of 0.98. ALX Oncology has a 1-year low of $1.19 and a 1-year high of $17.83. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $1.62 and a 200-day moving average of $2.29.

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani bought 30,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the purchase, the director now owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 14,443 shares of company stock valued at $23,309. 33.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after purchasing an additional 6,888 shares during the last quarter. Hsbc Holdings PLC bought a new stake in ALX Oncology during the 2nd quarter worth approximately $63,000. GSA Capital Partners LLP acquired a new position in ALX Oncology in the 3rd quarter valued at approximately $88,000. Barclays PLC raised its stake in shares of ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after acquiring an additional 42,185 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares during the period. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.